04:39 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

Stabilizing the closed form of RyR2 for nephrotic syndrome

DISEASE CATEGORY: Renal INDICATION: Renal damage Preventing podocyte injury by stabilizing the closed form of the calcium channel RyR2 could treat nephrotic syndrome. Phosporylation of RyR2's serine at position 2808 (S2808) causes calcium leakage through...
23:34 , Sep 14, 2017 |  BC Innovations  |  Strategy

Numerate’s Intelligence

With three new partnerships formed since June, Numerate Inc. is picking up steam and demonstrating that industry and academic groups alike are finding utility in its AI platform, which can build robust predictive models for...
20:23 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

InCarda's inhaled flecainide well tolerated in Phase I

InCarda Therapeutics Inc. (San Francisco, Calif.) reported top-line data from an Australian Phase I trial in 40 healthy volunteers showing that single doses of 20-60 mg InRhythm inhaled flecainide were well tolerated. The company also...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Inhaled flecainide: Phase I started

InCarda began a double-blind, placebo-controlled, Australian Phase I trial to evaluate single ascending doses of inhaled flecainide in 38 healthy volunteers. InCarda Therapeutics Inc. , San Francisco, Calif.   Product: Inhaled flecainide ( InRhythm )...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Ryanodine receptor 1 (RyR1); RyR2 Studies in mice suggest ryanodine receptor agonists could be useful for treating AD....
07:00 , Sep 20, 2012 |  BC Innovations  |  Targets & Mechanisms

Stabilizing RyR2

A group at Columbia University has found that preventing the leak of calcium ions from ryanodine receptors could help treat post-traumatic stress disorder, and a French team has found that the strategy could be effective...
07:00 , Sep 13, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder Ryanodine receptor 2 (RyR2) Mouse studies suggest stabilizing RyR2 could help prevent post-traumatic stress disorder. In mice, an RyR2-stabilizing protein prevented chronic...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiomyopathy Ryanodine receptor 2 (RyR2) Mouse studies suggest that inhibiting protein kinase A (PKA)-mediated phosphorylation of RyR2 could help treat cardiomyopathy associated with Duchenne...
07:00 , Jul 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) NK cells Studies in patient-derived cells and in mice suggest that depleting NK cells in arthritic joints could help treat RA....